{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:52:15Z","timestamp":1777006335337,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National Key Research and Development Program of China","award":["2022YFA1103300"],"award-info":[{"award-number":["2022YFA1103300"]}]},{"name":"the Natural Science Foundation of Beijing","award":["Z230016"],"award-info":[{"award-number":["Z230016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06591-9","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T01:29:44Z","timestamp":1759109384000},"page":"5537-5541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of transplantation-associated thrombotic microangiopathy with iptacopan: two cases report"],"prefix":"10.1007","volume":"104","author":[{"given":"Jun","family":"Kong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dao-Xing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Dong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"3","key":"6591_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","volume":"29","author":"ML Schoettler","year":"2023","unstructured":"Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S et al (2023) Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 29(3):151\u201363. https:\/\/doi.org\/10.1016\/j.jtct.2022.11.015","journal-title":"Transplant Cell Ther."},{"key":"6591_CR2","doi-asserted-by":"publisher","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J et al (2024) Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update. Cancer Lett. 605. https:\/\/doi.org\/10.1016\/j.canlet.2024.217264","DOI":"10.1016\/j.canlet.2024.217264"},{"issue":"3","key":"6591_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3760\/cma.j.issn.0253-2727.2021.03.001","volume":"42","author":"Hematopoietic Stem Cell Application Group CSoHCMA","year":"2021","unstructured":"Hematopoietic Stem Cell Application Group CSoHCMA (2021) Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy (2021). Zhonghua Xue Ye Xue Za Zhi. 42(3):177\u201384. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2021.03.001","journal-title":"Zhonghua Xue Ye Xue Za Zhi."},{"issue":"2","key":"6591_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/bmt.2017.207","volume":"53","author":"J Khosla","year":"2018","unstructured":"Khosla J, Yeh AC, Spitzer TR, Dey BR (2018) Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. Bone Marrow Transplant. 53(2):129\u201337. https:\/\/doi.org\/10.1038\/bmt.2017.207","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"6591_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41409-022-01852-x","volume":"58","author":"P Svec","year":"2023","unstructured":"Svec P, Elfeky R, Galimard JE, Higham CS, Dalissier A, Quigg TC et al (2023) Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study. Bone Marrow Transplant. 58(2):129\u201341. https:\/\/doi.org\/10.1038\/s41409-022-01852-x","journal-title":"Bone Marrow Transplant."},{"issue":"13","key":"6591_CR6","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","volume":"135","author":"S Jodele","year":"2020","unstructured":"Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC et al (2020) Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 135(13):1049\u201357. https:\/\/doi.org\/10.1182\/blood.2019004218","journal-title":"Blood."},{"issue":"12","key":"6591_CR7","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood.2023022526","volume":"143","author":"S Jodele","year":"2024","unstructured":"Jodele S, Dandoy CE, Aguayo-Hiraldo P, Lane A, Teusink-Cross A, Sabulski A et al (2024) A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation\u2013associated TMA. Blood 143(12):1112-1123. https:\/\/doi.org\/10.1182\/blood.2023022526","journal-title":"Blood."},{"issue":"5","key":"6591_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40265-024-02009-4","volume":"84","author":"YY Syed","year":"2024","unstructured":"Syed YY (2024) Iptacopan: First Approval. Drugs. 84(5):599\u2013606. https:\/\/doi.org\/10.1007\/s40265-024-02009-4","journal-title":"Drugs."},{"key":"6591_CR9","doi-asserted-by":"crossref","unstructured":"Peffault de Latour R, Roth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, et al. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2024;390(11):994\u20131008. doi: 10.1056\/NEJMoa2308695.","DOI":"10.1056\/NEJMoa2308695"},{"issue":"3","key":"6591_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.21147\/j.issn.1000-9604.2025.03.10","volume":"37","author":"Q Wen","year":"2025","unstructured":"Wen Q, Jiang C, Liu X, Xia Y, Ma Y, Yang Y et al (2025) Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group. Chin J Cancer Res. 37(3):417\u201331. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2025.03.10","journal-title":"Chin J Cancer Res."},{"key":"6591_CR11","doi-asserted-by":"crossref","unstructured":"Wang Y, Gao X, Wang T, Zhang X, Xu L, Wang Y, et al. Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donor vs. identical sibling donor hematopoietic stem cell transplantation in acute myeloid leukemia. Chin J Cancer Res. 2024;36(5):530\u2009\u2212\u200944. doi: 10.21147\/j.issn.1000-9604.2024.05.06.","DOI":"10.21147\/j.issn.1000-9604.2024.05.06"},{"key":"6591_CR12","doi-asserted-by":"crossref","unstructured":"Mahmoudjafari Z, Alencar MC, Alexander MD, Johnson DJ, Yeh J, Evans MD. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy and the role of advanced practice providers and pharmacists. Bone Marrow Transplant. 2023;58(6):625\u2009\u2212\u200934. doi: 10.1038\/s41409-023-01951-3.","DOI":"10.1038\/s41409-023-01951-3"},{"key":"6591_CR13","unstructured":"Shi YM, Zhang FK. [Advances in complement inhibition therapy for paroxysmal nocturnal hemoglobinuria]. Zhonghua Xue Ye Xue Za Zhi. 2025;46(1):90\u2009\u2212\u20096. doi: 10.3760\/cma.j.cn121090-20240903-00332."},{"key":"6591_CR14","doi-asserted-by":"crossref","unstructured":"14. Khaled SK, Claes K, Goh YT, Kwong YL, Leung N, Mendrek W, et al. Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. J Clin Oncol. 2022;40(22):2447-57. doi: 10.1200\/JCO.21.02389.","DOI":"10.1200\/JCO.21.02389"},{"key":"6591_CR15","unstructured":"Schoettler M BD, Krauss A, Chaudhury S, Bachman E, Qin M, et al. Ravulizumab plus best supportive care to treat pediatric patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy: first results from a phase 3 trial. EHA Library. 2025."},{"key":"6591_CR16","doi-asserted-by":"crossref","unstructured":"Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29(4):319\u2009\u2212\u200929. doi: 10.1097\/QCO.0000000000000279.","DOI":"10.1097\/QCO.0000000000000279"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06591-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06591-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06591-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:19:02Z","timestamp":1763194742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06591-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":16,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6591"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06591-9","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"3 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The use of iptacopan in these two patients was approved by the Institutional Review Board of Peking University People\u2019s Hospital. At the time of iptacopan initiation, the first patient was unconscious; treatment consent was therefore provided by his next-of-kin, who later also gave consent for publication. The second patient provided written informed consent for both treatment and publication. All procedures were conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval\u00a0<!--Emphasis Type='Bold' removed-->and consent to publish"}}]}}